Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions

Thomas Anchordoquy; Natalie Artzi; Irina V. Balyasnikova; Yechezkel Barenholz; Ninh M. La-Beck; Jacob S. Brenner; Warren C.W. Chan; Paolo Decuzzi; Agata A. Exner; Alberto Gabizon; Biana Godin; Samuel K. Lai; Twan Lammers; Michael J. Mitchell; S. Moein Moghimi; Vladimir R. Muzykantov; Dan Peer; Juliane Nguyen; Rachela Popovtzer; Madison Ricco; Natalie J. Serkova; Ravi Singh; Avi Schroeder; Anna A. Schwendeman; Joelle P. Straehla; Tambet Teesalu; Scott Tilden; Dmitri Simberg

doi:10.1021/acsnano.4c00182

Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions

Thomas Anchordoquy, Natalie Artzi, Irina V. Balyasnikova, Yechezkel Barenholz, Ninh M. La-Beck, Jacob S. Brenner, Warren C.W. Chan, Paolo Decuzzi, Agata A. Exner, Alberto Gabizon, Biana Godin, Samuel K. Lai, Twan Lammers, Michael J. Mitchell, S. Moein Moghimi, Vladimir R. Muzykantov, Dan Peer, Juliane Nguyen, Rachela Popovtzer, Madison RiccoNatalie J. Serkova, Ravi Singh, Avi Schroeder, Anna A. Schwendeman, Joelle P. Straehla, Tambet Teesalu, Scott Tilden, Dmitri Simberg

Research output: Contribution to journal › Review article › peer-review

Abstract

In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop “Mechanisms and Barriers in Nanomedicine” in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.

Original language	English (US)
Pages (from-to)	13983-13999
Number of pages	17
Journal	ACS Nano
Volume	18
Issue number	22
DOIs	https://doi.org/10.1021/acsnano.4c00182
State	Published - Jun 4 2024

Keywords

barriers
complement
delivery
formulation
inflammation
mRNA
nanomedicine
translation
tumor

ASJC Scopus subject areas

Materials Science(all)
Engineering(all)
Physics and Astronomy(all)

Access to Document

10.1021/acsnano.4c00182

Cite this

Anchordoquy, T., Artzi, N., Balyasnikova, I. V., Barenholz, Y., La-Beck, N. M., Brenner, J. S., Chan, W. C. W., Decuzzi, P., Exner, A. A., Gabizon, A., Godin, B., Lai, S. K., Lammers, T., Mitchell, M. J., Moghimi, S. M., Muzykantov, V. R., Peer, D., Nguyen, J., Popovtzer, R., ... Simberg, D. (2024). Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions. ACS Nano, 18(22), 13983-13999. https://doi.org/10.1021/acsnano.4c00182

Anchordoquy, T, Artzi, N, Balyasnikova, IV, Barenholz, Y, La-Beck, NM, Brenner, JS, Chan, WCW, Decuzzi, P, Exner, AA, Gabizon, A, Godin, B, Lai, SK, Lammers, T, Mitchell, MJ, Moghimi, SM, Muzykantov, VR, Peer, D, Nguyen, J, Popovtzer, R, Ricco, M, Serkova, NJ, Singh, R, Schroeder, A, Schwendeman, AA, Straehla, JP, Teesalu, T, Tilden, S & Simberg, D 2024, 'Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions', ACS Nano, vol. 18, no. 22, pp. 13983-13999. https://doi.org/10.1021/acsnano.4c00182

@article{e76c743d50174b1b83a1614bb8fd2bb6,

title = "Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions",

abstract = "In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop “Mechanisms and Barriers in Nanomedicine” in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.",

keywords = "barriers, complement, delivery, formulation, inflammation, mRNA, nanomedicine, translation, tumor",

author = "Thomas Anchordoquy and Natalie Artzi and Balyasnikova, {Irina V.} and Yechezkel Barenholz and La-Beck, {Ninh M.} and Brenner, {Jacob S.} and Chan, {Warren C.W.} and Paolo Decuzzi and Exner, {Agata A.} and Alberto Gabizon and Biana Godin and Lai, {Samuel K.} and Twan Lammers and Mitchell, {Michael J.} and Moghimi, {S. Moein} and Muzykantov, {Vladimir R.} and Dan Peer and Juliane Nguyen and Rachela Popovtzer and Madison Ricco and Serkova, {Natalie J.} and Ravi Singh and Avi Schroeder and Schwendeman, {Anna A.} and Straehla, {Joelle P.} and Tambet Teesalu and Scott Tilden and Dmitri Simberg",

note = "Publisher Copyright: {\textcopyright} 2024 American Chemical Society.",

year = "2024",

month = jun,

day = "4",

doi = "10.1021/acsnano.4c00182",

language = "English (US)",

volume = "18",

pages = "13983--13999",

journal = "ACS Nano",

issn = "1936-0851",

publisher = "American Chemical Society",

number = "22",

}

TY - JOUR

T1 - Mechanisms and Barriers in Nanomedicine

T2 - Progress in the Field and Future Directions

AU - Anchordoquy, Thomas

AU - Artzi, Natalie

AU - Balyasnikova, Irina V.

AU - Barenholz, Yechezkel

AU - La-Beck, Ninh M.

AU - Brenner, Jacob S.

AU - Chan, Warren C.W.

AU - Decuzzi, Paolo

AU - Exner, Agata A.

AU - Gabizon, Alberto

AU - Godin, Biana

AU - Lai, Samuel K.

AU - Lammers, Twan

AU - Mitchell, Michael J.

AU - Moghimi, S. Moein

AU - Muzykantov, Vladimir R.

AU - Peer, Dan

AU - Nguyen, Juliane

AU - Popovtzer, Rachela

AU - Ricco, Madison

AU - Serkova, Natalie J.

AU - Singh, Ravi

AU - Schroeder, Avi

AU - Schwendeman, Anna A.

AU - Straehla, Joelle P.

AU - Teesalu, Tambet

AU - Tilden, Scott

AU - Simberg, Dmitri

PY - 2024/6/4

Y1 - 2024/6/4

N2 - In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop “Mechanisms and Barriers in Nanomedicine” in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.

AB - In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop “Mechanisms and Barriers in Nanomedicine” in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.

KW - barriers

KW - complement

KW - delivery

KW - formulation

KW - inflammation

KW - mRNA

KW - nanomedicine

KW - translation

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=85194029254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85194029254&partnerID=8YFLogxK

U2 - 10.1021/acsnano.4c00182

DO - 10.1021/acsnano.4c00182

M3 - Review article

C2 - 38767983

AN - SCOPUS:85194029254

SN - 1936-0851

VL - 18

SP - 13983

EP - 13999

JO - ACS Nano

JF - ACS Nano

IS - 22

ER -

Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this